TP53 and acute myeloid leukemia: Similarly, the study by Della Porta et al confirmed the independent clinical significance of mutation screening of ASXL1, RUNX1, and TP53 genes in predicting survival after allogeneic HSCT for patients with MDS and MDS/AML [18].